## **Core Concept**
The question tests knowledge on the association between certain medications and the risk of developing hypertrophic pyloric stenosis (HPS), a condition characterized by thickening of the pylorus muscle leading to gastric outlet obstruction. This condition is particularly noted in infants.

## **Why the Correct Answer is Right**
The correct answer, **Erythromycin**, is a macrolide antibiotic known to cause hypertrophic pyloric stenosis in infants. This is due to its motilin receptor agonist activity. Motilin is a hormone that stimulates gastrointestinal motility. Erythromycin, at high doses or with prolonged use, can stimulate these receptors in the gastrointestinal tract, potentially leading to abnormal muscle growth and HPS.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Without a specified drug, it's impossible to assess its accuracy, but given the context, it's not erythromycin.
- **Option B:** Similarly, without a specified drug, we cannot evaluate its correctness.
- **Option C:** Again, lacking a specific drug, we can't assess its validity.
- **Option D:** This option is also unspecified and thus cannot be evaluated.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that erythromycin, especially when used in infants, carries a risk of inducing hypertrophic pyloric stenosis. This association is well-documented and serves as a critical consideration in pediatric prescribing practices.

## **Correct Answer: C. Erythromycin.**